Objective: The utility of rapid on-site evaluation during endobronchial ultrasound with a guide sheath for peripheral pulmonary lesions is unclear. The aim of this study was to evaluate the role of rapid on-site evaluation during endobronchial ultrasound with a guide sheath for peripheral pulmonary lesions. Methods: Consecutive patients who underwent endobronchial ultrasound with a guide sheath for the diagnosis of peripheral pulmonary lesions at our hospital between September 2012 and July 2014 were included in this retrospective study. Cytology slides were air-dried, and modified Giemsa (Diff-Quik) staining was used for rapid on-site evaluation. Additional smears were prepared for Papanicolaou staining and tissue samples were placed in formalin for histologic evaluation. The results of rapid on-site evaluation were compared with the final diagnoses of endobronchial ultrasound with a guide sheath. Results: A total of 718 cases were included in the study population. The sensitivity, specificity, positive predictive value, negative predictive value and diagnostic accuracy of rapid on-site evaluation during endobronchial ultrasound with a guide sheath for peripheral pulmonary lesions was 88.6%, 65.9%, 81.2%, 77.7% and 80.1%, respectively. There were no procedure-related deaths. Conclusions: Rapid on-site evaluation during endobronchial ultrasound with a guide sheath had high sensitivity for peripheral pulmonary lesions. When carrying out rapid on-site evaluation of transbronchial biopsy samples from peripheral pulmonary lesions, careful interpretation and clinical correlation are necessary.
Introduction
Transbronchial biopsy (TBB) with flexible bronchoscopy has become a more common procedure for obtaining specimen from peripheral pulmonary lesions (PPLs). Although central endobronchial tumors can be accurately diagnosed bronchoscopy, the diagnostic yield for PPLs was reported to be only 60%-70%, even with a combination of various techniques (1) . Endobronchial ultrasound with a guide sheath (EBUS-GS) is considered one of the minimally invasive and safe procedures to get samples from PPLs (2) . According to a recent randomized study, the diagnostic yield of EBUS-GS with virtual bronchoscopic navigation (VBN) was around 60% (3) . During an EBUS-GS procedure, biopsy forceps, brush and flushing of GS have been investigated as tools to obtain diagnostic specimens from PPLs after localization of EBUS images (4) . However, some cases cannot be diagnosed even if PPLs were confirmed by EBUS (5) .
There have been several reports on the use of rapid on-site cytology evaluation (ROSE) (6,7) during endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA), which is a minimally invasive and highly accurate modality for the diagnosis of lymph node metastasis in lung cancer (8, 9) . In EBUS-TBNA, the presence of a cytopathologist who performed ROSE during the procedure reduced futile, additional biopsies while preserving the diagnostic yield (10) . A randomized trial showed that ROSE during EBUS-TBNA significantly reduced the number of needle passes and complication rates (11) . In addition, a high concordance rate was reported between ROSE and histologic diagnosis (12) . However, there have been no studies on the value of ROSE in the diagnostic yield of EBUS-TBNA. In fact, current guidelines suggested that evidence is insufficient to recommend ROSE during every EBUS-TBNA procedure (13, 14) .
However, there were only few reports of ROSE during diagnostic bronchoscopy for PPLs. Based on the results by a Japanese research group, ROSE improved the diagnostic yield of fluoroscopyguided bronchoscopic sampling of PPLs (15, 16) . Recently, electromagnetic navigation (EMN) bronchoscopy, a novel technology enabling PPL localization, has increased the diagnostic yield of TBB (17) . Some studies reported that EMN with ROSE was associated with high diagnostic yield while avoiding risks and more invasive procedures (18) (19) (20) (21) .
EBUS-GS is another important diagnostic bronchoscopy procedure for PPLs (22) (23) (24) , including ground glass opacity (GGO) lesions (25) . The diagnostic utility and accuracy of ROSE of bronchoscopic brushings were reported (26) , but there were very few studies on the utility of ROSE for diagnosing PPLs during EBUS-GS. This study aimed to correlate the results of ROSE, final diagnosis and features of PPLs during EBUS-GS.
Patients and methods

Subjects
The database of the Respiratory Endoscopy Division of the National Cancer Center, Tokyo, Japan, was searched for patients who underwent EBUS-GS for PPL diagnosis between September 2012 and July 2014. The medical records of the study population were reviewed and evaluated. PPL was defined as an abnormal growth that was surrounded by pulmonary parenchyma and was bronchoscopically invisible. This study was approved by the National Cancer Center Institutional Review Board. Written informed consent for bronchoscopy was obtained from all patients; additional informed consent for this study was waived due to the design of retrospective chart review for clinical history and diagnostic results.
Biopsy procedure by EBUS-GS
Flexible bronchoscopy was done using a fiberoptic bronchoscope in combination with the R-EBUS probe (20 MHz mechanical-radial type, UM-S20-20R or UM-S20-17S; Olympus, Japan) and GS kit (K-201 or K-203; Olympus, Japan). The location of the bronchus leading to the lesion was planned in advance by using highresolution chest computed tomography or VBN (Ziostation2; Ziosoft Ltd, Tokyo, Japan; LungPoint; Bronchus Ltd, Mountain View, CA, USA; or DirectPath, Olympus Ltd, Tokyo, Japan). The scope was inserted through the oral route, and each procedure was done under local anesthesia with intravenous administration of midazolam for mild sedation. X-ray fluoroscopy (VersiFlex VISTA, Hitachi, Japan) was used to guide the insertion of the R-EBUS probe with GS through the working channel of the bronchoscope until the target site was reached.
After confirming the location of the R-EBUS probe and GS within a target lesion, TBB using forceps and brush cytology were carried out for specimen collection. When the R-EBUS probe was adjacent to or outside the target lesion, the bronchus closest to the PPL was meticulously searched under fluoroscopy prior to specimen collection. Fluoroscopy guidance was used during biopsy and brush sampling, as well as during removal of the GS after sampling. Procedure time was measured based on the interval between insertion and removal of the bronchoscope through the vocal cords.
Processing of specimens
The materials from cytology brush or forceps biopsy imprint cytology were smeared onto two glass slides. One slide was rapidly air-dried and stained with modified Giemsa (Diff-Quik; Sysmex Ltd., Kobe, Japan), whereas the other slide was fixed in 95% alcohol for Papanicolaou staining. After every sampling, the remaining cells in the brush and forceps were rinsed off in saline. Microscopic examination of the slide preparation with Diff-Quik stain was performed at the same bronchoscopy unit during the EBUS-GS procedure by a certificated cytology specialist: this way, the ROSE diagnosis was communicated immediately to the bronchoscopists.
Tissue biopsy samples were placed in 10% formalin and were embedded in paraffin for routine histologic evaluation on hematoxylin and eosin staining.
Outcome of ROSE and final diagnoses of EBUS-GS
The samples were categorized as positive for malignancy or negative for malignancy based on the results of ROSE, which were compared with the final diagnoses of EBUS-GS.
The criteria for a positive final diagnosis of EBUS-GS were (i) malignant lesion as determined by histologic features or Class IV/V cytology on Papanicolaou stain and (ii) benign lesion as determined by histologic features, the presence of bacteria on culture.
Statistical analysis
Descriptive statistics were presented as frequency, percentage and median (range). The sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and diagnostic accuracy of ROSE during EBUS-GS were derived based on the corresponding final pathologic diagnosis. Statistical analyses were done using EZR (Saitama Medical Center, Jichi Medical University, Saitama, Japan), which is a graphical user interface for R (The R foundation for Statistical Computing, Vienna, Austria).
Results
ROSE during EBUS-GS was performed for 718 consecutive PPLs during the study period. A summary of patient demographics and clinical information is shown in Table 1 . The study population had a median age of 69 years (29-91) and mostly consisted of male patients. The median lesion size was 26.0 mm (7.0-107.0). Of 718 PPLs, 551 were solid lesions and 167 were GGO lesions. The tumor locations were the upper lobe (n = 360), middle/lingular lobe (n = 94) and lower lobe (n = 264).The EBUS image before sampling was 'Within' in 416 lesions (57.9%), 'Adjacent to' in 213 lesions (29.7%) and 'Invisible' in 89 lesions (20.4%). Median procedure time was 22 minutes (5.0-55.0). A total of 590 lesions (82.2%) were finally diagnosed as malignant.
The final pathologic diagnoses of EBUS-GS were as follows: 317 cases of adenocarcinoma, 67 cases of squamous cell carcinoma, 24 cases of non-small cell carcinoma, 10 cases of small cell carcinoma, 31 cases of other histologic types (including 1 MALT lymphoma, 1 carcinoid and 29 metastatic malignancies) and 270 cases of benign lesions, including non-specific inflammatory changes in 248, cryptogenic organizing pneumonia in 12, bacterial infections in 3, mycobacterium avium complex infection in 3, fungal infection in 2 and hamartoma in 2. There were four patients (0.6%) who developed pneumothorax and four patients (0.6%) who developed pulmonary infection after the procedure. There was no case of procedurerelated death.
Correlation between EBUS-GS results and final pathologic diagnosis
The results of EBUS-GS correlated with the final pathologic diagnosis of the patients. Using the final pathologic diagnosis of the patients as the standard, EBUS-GS had 75.9% sensitivity, 100% specificity, 100% PPV, 47.4% NPV and 80.2% diagnostic accuracy (Table 2) .
Correlation between ROSE and pathologic results of EBUS-GS
The results of ROSE correlated with the final pathologic diagnosis of EBUS-GS. There was a discrepancy between the results of ROSE and the final pathologic diagnosis of EBUS-GS in 143 cases. Of 489 cases that were positive on ROSE, 92 were negative on final pathologic diagnosis. With the final pathologic diagnosis as the standard, ROSE had 88.6% sensitivity, 65.9% specificity, 81.2% PPV, 77.7% NPV and 80.1% diagnostic accuracy (Table 3) .
For solid PPLs, ROSE correlated with the final pathologic diagnosis of EBUS-GS. There was a discrepancy between the results of ROSE and the final pathologic diagnosis in 101 cases. Of 377 cases that were positive on ROSE, 61 were negative on final pathologic diagnosis. With the final pathologic diagnosis as the standard, ROSE had 88.8% sensitivity, 68.7% specificity, 83.8% PPV, 77.0% NPV and 81.7% diagnostic accuracy (Table 4) .
For GGO PPLs, the results of ROSE correlated with the final pathologic diagnosis of EBUS-GS. There was a discrepancy between the results of ROSE and the final pathologic diagnosis in 42 cases. Of 112 cases that were positive on ROSE, 31 were negative on final pathologic diagnosis. With the final pathologic diagnosis as the standard, ROSE had 88.8% sensitivity, 58.7% specificity, 72.3% PPV, 80.0% NPV and 74.9% diagnostic accuracy (Table 5) .
Discussion
To the best of our knowledge, this is the first report about the utility of ROSE during EBUS-GS for PPLs, including GGO lesions. EBUS-GS was reported to be useful in the diagnosis of PPLs (22) . Although the use of EBUS-GS gives a relatively high diagnostic yield compared with conventional TBB, further improvement of the diagnostic efficacy of bronchoscopy for PPLs is desired. During EBUS-TBNA, ROSE has been demonstrated to reduce the number of needle punctures (6) . To the best of our knowledge, reports on ROSE during EBUS-GS of PPLs are few and focused on solid lesions (26) . Therefore, its utility for all PPLs remains unknown.
In this study, we examined the utility of ROSE during EBUS-GS for the diagnosis of both solid and GGO PPLs. Our results showed that ROSE during EBUS-GS had high sensitivity for PPLs; however, its specificity and overall diagnostic efficacy were lower compared with ROSE during EBUS-TBNA (7). Although our certified cytology specialist had >20 years of experience, there were many difficulties when deciding between malignancy and non-malignancy on ROSE. We considered that the presence of bronchial ciliated epithelium, bronchial cartilage and abundant inflammatory cells, such as macrophages and neutrophils, around the PPLs made ROSE for such Data are presented as median (range) or number (%). EBUS-GS, endobronchial ultrasound with a guide sheath; GGO, ground glass opacity; EBUS, endobronchial ultrasound; NSCLC, non-small cell lung cancer; MALT, mucosa-associated lymphoid tissue. Malignant  448  0  448  Benign  142  128  270  Total  590  128  718 Sensitivity = 75.9%, Specificity = 100%, PPV = 100%, NPV = 47.4%, diagnostic accuracy = 80.2%.
PPL, peripheral pulmonary lesion; PPV, positive predictive value; NPV, negative predictive value. lesions more difficult than that for lymph nodes. For example, marked inflammatory changes from non-malignant lesions around the PPLs were difficult to distinguish from those for malignancy because of similar features on ROSE. Therefore, the results of ROSE of PPL samples during EBUS-GS should be interpreted with caution and correlated with the clinical presentation of the patient.
The diagnostic efficacy of ROSE was better for solid lesions than GGO lesions. This may be explained by the fact that GGO lesions usually contain cells that are in the early stages of differentiation, which makes diagnosis by cytology per se a challenge (4, 25, 27) . Moreover, the method of Diff-Quik staining for ROSE that we used in this study may be disadvantageous in terms of distinguishing cytoplasm from mucus and blood.
The presence of debris, artifacts, alveolar epithelial cells or accompanying inflammatory cells on the slide preparations may explain the cases that were not definitively diagnosed by EBUS-GS despite the use of ROSE. Limitations of procedural techniques, like in cases wherein the sampling device could not reach the PPL, may have confounded our results as well.
We highlighted some valuable uses of ROSE during EBUS-GS for PPLs. On-site examination during EBUS-GS will guide bronchoscopists in determining whether a PPL has been accurately sampled. This is important for improving not only the yield but also the skills of the physicians. ROSE also enables triage of samples for subsequent investigations (28, 29) . For example, if ROSE shows that there are several neutrophils or macrophages, bacterial culture would be recommended. Another important role of ROSE during EBUS-GS of PPLs is for the diagnosis of lung cancer, which has recently been reported to be performed more often on small biopsy and cytologic samples. Specifically, ROSE may guide bronchoscopists in obtaining adequate samples for further classification, for detailed biological characterization (30) and for molecular analysis for epidermal growth factor receptor mutation or anaplastic lymphoma kinase rearrangement in lung cancer, especially advanced cases.
One limitation of this study was its retrospective and singlecenter design. A prospective, randomized, multicenter study would be ideal to confirm the value of ROSE during EBUS-GS, especially in improving diagnostic yield. In this study, we used the Diff-Quik staining, which is a modification of the Wright-Giemsa stain; whereas other studies used modified Shorr stain for slide preparations (16) . Different staining methods for the preparation of lymph node TBNA specimens were reported to be associated with varying sensitivity (31) (32) (33) . These results suggested a need to examine the optimal staining method for ROSE in future studies. Nevertheless, ROSE may be an important step to optimize the sampling procedures during EBUS-GS, but we will need a well-designed, randomized controlled study to support this hypothesis.
Conclusions
ROSE during EBUS-GS had high sensitivity for PPLs. When carrying out ROSE of TBB samples from PPLs, it may be necessary to carefully interpret and correlate the results with the clinical presentation. Further studies are required to determine the optimal staining method and to develop the criteria for ROSE examination for EBUS-GS.
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